Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Kazia Therapeutics Paxalisib Achieves 100% Clinical Benefit Rate in TNBC
Kazia Therapeutics Paxalisib Achieves 100% Clinical Benefit Rate in TNBC
Read also
HHS to allow US pharmacies to sell six FDA-unapproved peptides — Fortune
An HHS policy could allow US compounding pharmacies to sell six FDA-unapproved peptides despite unresolved safety and efficacy concerns.
Pfizer Ends Premarin Hormone Therapy Sales in Canada After Internal Review
Pfizer is ending Premarin cream and tablet sales in Canada after an internal review, with remaining tablet supplies expected to last until mid-2027.
FDA Approves Bayer's Asundexian Pill to Lower Recurrent Stroke Risk by 26%
The FDA approved Bayer’s Sunharbo (asundexian) after trial data showed a 26% lower relative risk of recurrent ischemic stroke with antiplatelets.
Takeda Launches Orzeyful for Narcolepsy After Rapid DEA Schedule IV Review
Takeda launches Orzeyful (oveporexton) for narcolepsy type 1 in the US after a rapid DEA review grants the oral drug Schedule IV classification.